Scientific publications

Adjuvants for allergy immunotherapeutics

Aug 21, 2017 | Magazine: Human Vaccines & Immunotherapeutics

Gamazo C (1), D Amelio C (2), Gastaminza G (3), Ferrer M (4), Irache JM (5).


Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response.

This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least two major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies.

This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays.

CITATION  Hum Vaccin Immunother. 2017 Oct 3;13(10):2416-2427. doi: 10.1080/21645515.2017.1348447.